| Q33358934 | Altered gene expression in highly purified enterocytes from patients with active coeliac disease |
| Q36256405 | Anemia is a common but neglected complication of adjuvant chemotherapy for early breast cancer |
| Q36563542 | Antiangiogenic therapy for cancer: an update |
| Q34068226 | Association Between Pharmaceutical Support and Basic Science Research on Erythropoiesis-Stimulating Agents |
| Q37610106 | Autocrine/paracrine erythropoietin regulates migration and invasion potential and the stemness of human breast cancer cells |
| Q54380871 | Autocrine/paracrine erythropoietin signalling promotes JAK/STAT-dependent proliferation of human cervical cancer cells. |
| Q37151778 | Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway |
| Q82573739 | EPO-R expression patterns in resected gastric adenocarcinoma followed by adjuvant chemoradiation treatment |
| Q86893314 | Erythropoietin |
| Q40361909 | Erythropoietin disrupts hypoxia-inducible factor signaling in ovarian cancer cells |
| Q53646442 | Erythropoietin downregulates bax and DP5 proapoptotic gene expression in neonatal hypoxic-ischemic brain injury. |
| Q38437717 | Erythropoietin in thyroid cancer |
| Q40365100 | Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia |
| Q39608875 | Erythropoietin protects pancreatic β-cell line NIT-1 cells against cytokine-induced apoptosis via phosphatidylinositol 3-kinase/Akt signaling |
| Q39486076 | Erythropoietin receptor contributes to melanoma cell survival in vivo. |
| Q40012704 | Expression of EPO receptor in pancreatic cells and its effect on cell apoptosis |
| Q81138488 | Expression of bcl-2 is associated with microvessel density in olfactory neuroblastoma |
| Q26866922 | Hematopoietic growth factors: personalization of risks and benefits |
| Q42136071 | Induction of erythropoietin increases the cell proliferation rate in a hypoxia-inducible factor-1-dependent and -independent manner in renal cell carcinoma cell lines |
| Q45212121 | Lack of expression and function of erythropoietin receptors in the kidney |
| Q36311491 | Long-term results of radiation therapy oncology group 9903: a randomized phase 3 trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiation therapy for squamous cell carcinoma of the head and nec |
| Q36167426 | Oxygen in the cultivation of stem cells |
| Q36353524 | Quantification of hypoxia-related gene expression as a potential approach for clinical outcome prediction in breast cancer |
| Q37164573 | RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells |
| Q39734169 | Testosterone membrane-initiated action in breast cancer cells: Interaction with the androgen signaling pathway and EPOR. |
| Q36219651 | The development of erythropoietic agents in oncology |
| Q34291437 | The effect of erythropoietin on normal and neoplastic cells |
| Q36718130 | Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review |